Prevalence of multiple antipsychotic use and associated adverse effects in Australians with mental illness

International Journal of Evidence-Based Healthcare

Volumn 14, Issue 3, 2016, Pages 104-112

  Westaway, Kerrie ^a   Sluggett, Janet ^a   Alderman, Christopher ^a   Procter, Nicholas ^a   Roughead, Elizabeth ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Adverse effects; Mental illness; Multiple antipsychotics

Indexed keywords

NEUROLEPTIC AGENT;

AUSTRALIA; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMAN; MENTAL DISORDERS; POLYPHARMACY; PREVALENCE;

ANTIPSYCHOTIC AGENTS; AUSTRALIA; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MENTAL DISORDERS; POLYPHARMACY; PREVALENCE;

EID: 85008386001     PISSN: 17441595     EISSN: 17441609     Source Type: Journal    
DOI: 10.1097/XEB.0000000000000082     Document Type: Article

References (36)

1. Morgan VA, Waterreus A, Mackinnon A, et al. People living with psychotic illness 2010: report on the second Australian national survey Canberra, Australia: Commonwealth of Australia; 2011; 10p. Report No.: 2.
2. Buckley N, Calabretto H, Dowden J, et al. Australian Medicines Handbook. Adelaide, Australia: Australian Medicines Handbook Pty Ltd; 2015; 1099 p.
3. Waterreus A, Morgan VA, Castle D, et al. Medication for psychosis: consumption and consequences: the second Australian national survey of psychosis. Aust N Z J Psychiatry 2012; 46: 762-73.
4. Centorrino F, Goren J, Hennen J, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004; 161: 700-6.
5. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: treatment and management. United Kingdom. Nice Clinical Guideline 178. 2014. guidance. nice.org.uk/cg178. [Accessed 2 September 2015].
6. Goren J, Parks J, Ghinassi F, et al. When is antipsychotic polypharmacy supported by research evidence Implications for QI. Jt Comm J Qual Patient Saf 2008; 34: 571-82.
7. Tirupati S, Chua L. Obesity and metabolic syndrome in a psychiatric rehabilitation service. Aust N Z J Psychiatry 2007; 41: 606-10.
8. Vecchio D, Spence C. A review of antipsychotic polypharmacy, high-dose prescribing and evaluation of adherence to local physical health monitoring guidelines, within the assertive community team (ACT) at Rockingham Kwinana mental health service. Aust N Z J Psychiatry 2014; 48: 125-6.
9. Young S, Taylor M, Lawrie S. 'First do no harm.' a systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol 2015; 29: 353-62.
10. Galletly C, Castle D, Dark F, et al. Clinical practice guideline for schizophrenia and related disorders. Melbourne, Australia: The Royal Australian and New Zealand College of Psychiatrists; 2015; 96.
11. Dolovich L, Evans M, Allen M, et al. Optimal use recommendations for atypical antipsychotics: combination and high-dose treatment strategies in adolescents and adults with schizophrenia Washington, DC, USA: US Department of Health and Human Services; 2011; 9.
12. Lochmann van Bennekom M, Gijsman H, Zitman F. Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness. J Psychopharmacol 2013; 27: 327-36.
13. Fleischhacker W, Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol 2014; 17: 1083-93.
14. Aparasu R, Bhatara V, Gupta S. U.S. national trends in the use of antipsychotics during office visits 1998-2002. Ann Clin Psychiatry 2005; 17: 147-52.
15. Gallego J, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 2012; 138: 18-28.
16. Toteja N, Gallego J, Saito E, et al. Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment. Int J Neuropsychopharmacol 2014; 17: 1095-105.
17. Roughead E, Semple S, Rosenfeld E. Literature review: medication safety in Australia Sydney, Australia: Australian Commission on Safety and Quality in Health Care; 2013; 125.
18. Roughead E, Barratt J, Gilbert A. Medication-related problems commonly occurring in an Australian community setting. Pharmacoepidemiol Drug Saf 2004; 13: 83-7.
19. Roughead E, Semple S. Medication safety in acute care in Australia: where are we now? Part 1: a review of the extent and causes of medication problems 2002-2008. Aust New Zealand Health Policy 2009; 6: 1-12.
20. Gisev N, Bell JS, Chen TF. A retrospective study of psychotropic drug use among individuals with mental illness issued a community treatment order. Int J Clin Pract 2014; 68: 236-44.
21. Plever S, Emmerson B, Chapple B, et al. The Queensland Mental Health Clinical Collaborative and the management of schizophrenia. Australas Psychiatry 2010; 18: 106-14.
22. John A, Gee T, Alexander S, et al. Prevalence and nature of antipsychotic polypharmacy among inpatients with schizophrenia spectrum disorders at an Australian mental health service. Australas Psychiatry 2014; 22: 546-50.
23. Botvinik L, Ng C, Schweitzer I. Audit of antipsychotic prescribing in a private psychiatric hospital. Australas Psychiatry 2004; 12: 227-33.
24. Dean A, McDermott B, Marshall R. Psychotropic medication utilization in a child and adolescent mental health service. J Child Adolesc Psychopharmacol 2006; 16: 273-85.
25. Bains J, Nielssen O. Combining depot antipsychotic medications with novel antipsychotics in forensic patients: a practice in search of a principle. Psychiatr Bull 2003; 27: 14-6.
26. Martin A, O'Driscoll C, Samuels A. Clozapine use in a forensic population in a New South Wales prison hospital. Aust N Z J Psychiatry 2008; 42: 141-6.
27. Callaly T, Trauer T. Patterns of use of antipsychotic medication in a regional community mental health service. Australas Psychiatry 2000; 8: 220-4.
28. Lowe M, Chopra P, Herrman H. Mortality, prescribing patterns and intensive case management in community mental health care. Aust N Z J Psychiatry 2010; 44: 960- 1960.
29. Gisev N, Bell J, McLachlan A, et al. Psychiatric drug use among patients of a community mental health service: patterns and implications. Dis Manag Health Outcomes 2006; 14: 369-76.
30. Pai N, Laidlaw M, Vella S. Augmentation of clozapine with another pharmacological agent: treatment for refractory schizophrenia in the 'real world'. Acta Psychiatr Scand 2012; 126: 40-6.
31. Morgan V, Waterreus A, Jablensky A, et al. People living with psychotic illness in 2010: the second Australian national survey of psychosis. Aust N Z J Psychiatry 2012; 46: 735-52.
32. Galletly C, Foley D, Waterreus A, et al. Cardiometabolic risk factors in people with psychotic disorders: the second Australian national survey of psychosis. Aust N Z J Psychiatry 2012; 46: 753-61.
33. Gladigau E, Fazio T, Hannam J, et al. Increased cardiovascular risk in patients with severe mental illness. Intern Med J 2014; 44: 65-9.
34. Tani H, Uchida H, Suzuki T, et al. Interventions to reduce antipsychotic polypharmacy: a systematic review. Schizophr Res 2013; 143: 215-20.
35. Thompson A, Sullivan S, Barley M, et al. The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards: a cluster randomised controlled trial. Psychol Med 2008; 38: 705-15.
36. Mace S, Taylor D. Reducing the rates of prescribing highdose antipsychotics and polypharmacy on psychiatric inpatient and intensive care units: results of a 6-year quality improvement programme. Ther Adv Psychopharmacol 2015; 5: 4-12.